• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Seaport Calibre Materials Acquisition Corp. Announces It Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination

    2/1/23 9:00:00 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous
    Get the next $SCMA alert in real time by email

    NEW YORK, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Seaport Calibre Materials Acquisition Corp. (NASDAQ:SCMA) (the "Company") announced today that, because the Company will not consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation (the "Amended Charter"), the Company intends to dissolve and liquidate in accordance with the provisions of the Amended Charter, effective as of the close of business on February 1, 2023.

    On January 13, 2023, the Company filed with the Securities and Exchange Commission a definitive proxy statement (the "Proxy Statement") in connection with a special meeting of stockholders to consider and vote on certain proposals, including an extension of the date by which the Company has to complete an initial business combination from February 1, 2023 to August 1, 2023 (the "Extension"). As described in the Proxy Statement, the Company is unable to proceed with the Extension because the number of public shares subject to a redemption election will cause the Company to have less than $5,000,001 of net tangible assets following approval of the Extension.

    As a result, the Company will redeem all of the outstanding shares of Class A common stock (other than those already redeemed in connection with the Extension) that were included in the units issued in its initial public offering (the "Public Shares"), at a per-share redemption price of approximately $10.27.

    As of the close of business on February 1, 2023, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount.

    In order to provide for the disbursement of funds from the trust account, the Company will instruct the trustee of the trust account to take all necessary actions to liquidate the securities held in the trust account. The proceeds of the trust account will be held in a non-interest bearing account while awaiting disbursement to the holders of the Public Shares. Record holders will receive their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company's transfer agent. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the redemption amount. The redemption of the Public Shares is expected to be completed within ten business days after February 1, 2023.

    The Company's sponsor has agreed to waive its redemption rights with respect to its outstanding Class B common stock issued prior to the Company's initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless.

    The Company expects that the Nasdaq Stock Market LLC will file a Form 25 with the United States Securities and Exchange Commission (the "Commission") to delist the Company's securities. The Company thereafter expects to file a Form 15 with the Commission to terminate the registration of its securities under the Securities Exchange Act of 1934, as amended.

    Forward-Looking Statements

    This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and prospectus for the Company's initial public offering filed with the SEC, and subsequent reports filed with the SEC, as amended from time to time. Copies of these documents are available on the SEC's website, at www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

    Contact:

    Seaport Calibre Materials Acquisition Corp.

    212-616-7700



    Get the next $SCMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCMA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Barclays Plc

    4 - Seaport Calibre Materials Acquisition Corp. (0001863428) (Issuer)

    8/26/22 1:50:25 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    SEC Form 3: New insider Barclays Plc claimed ownership of 1,481,560 shares

    3 - Seaport Calibre Materials Acquisition Corp. (0001863428) (Issuer)

    8/26/22 10:39:08 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    $SCMA
    SEC Filings

    View All

    SEC Form 15-12G filed by Seaport Calibre Materials Acquisition Corp.

    15-12G - Seaport Calibre Materials Acquisition Corp. (0001863428) (Filer)

    2/13/23 4:33:20 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    SEC Form 25-NSE filed by Seaport Calibre Materials Acquisition Corp.

    25-NSE - Seaport Calibre Materials Acquisition Corp. (0001863428) (Subject)

    2/2/23 4:15:02 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    Seaport Calibre Materials Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - Seaport Calibre Materials Acquisition Corp. (0001863428) (Filer)

    2/1/23 9:10:38 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    $SCMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seaport Calibre Materials Acquisition Corp. Announces It Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination

    NEW YORK, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Seaport Calibre Materials Acquisition Corp. (NASDAQ:SCMA) (the "Company") announced today that, because the Company will not consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation (the "Amended Charter"), the Company intends to dissolve and liquidate in accordance with the provisions of the Amended Charter, effective as of the close of business on February 1, 2023. On January 13, 2023, the Company filed with the Securities and Exchange Commission a definitive proxy statement (the "Proxy Statement") in connection with a special meeting of stockholders to consider and vot

    2/1/23 9:00:00 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    Seaport Calibre Materials Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders

    NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Seaport Calibre Materials Acquisition Corp. (Nasdaq: SCMA) (the "Company") announced today that it has postponed the Company's Special Meeting of Stockholders to be held on January 26, 2023, until January 31, 2023, at 1:00 p.m. Eastern Time. The postponed Special Meeting will be completely virtual and stockholders will be able to attend the special meeting online, vote and submit questions by visiting https://www.cstproxy.com/seaportcalibreacquisition/2023. There will be no change in the record date as a result of this postponement, and proxies tendered prior to the postponed date will not need to be voted again. Stockholders may elect to redeem

    1/26/23 5:00:00 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    $SCMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Seaport Calibre Materials Acquisition Corp. (Amendment)

    SC 13G/A - Seaport Calibre Materials Acquisition Corp. (0001863428) (Subject)

    2/14/24 1:28:06 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    SEC Form SC 13G/A filed by Seaport Calibre Materials Acquisition Corp. (Amendment)

    SC 13G/A - Seaport Calibre Materials Acquisition Corp. (0001863428) (Subject)

    2/9/24 11:04:13 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    SEC Form SC 13G/A filed by Seaport Calibre Materials Acquisition Corp. (Amendment)

    SC 13G/A - Seaport Calibre Materials Acquisition Corp. (0001863428) (Subject)

    2/14/23 3:30:17 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous